How to Cite
Abstract
Introduction. The molecular picture of the development of HIF overexpression against VHL deficiency background is a key event associated with the manifestation and progression of clear cell renal cell carcinoma. However, this indicator's significance for the development of the disease and the formation of a response to targeted therapy is not clear. The study aimed to study the relationship between the expression and content of VHL in kidney cancer tissue with clinical, morphological parameters, mRNA level NF-κB p65, NF-κB p50, HIF-1, HIF-2, VEGF, and CAIX.
Material and methods. The study included 39 patients with renal cell carcinoma. The disease's localized form (T1-2N0M0) was diagnosed in 20 patients; 19 patients had a disseminated process (T1-3N0-1M1). The study's material was normal, and tumor tissue was obtained during the surgical stage of treatment. VHL expression was determined by real-time PCR. The pVHL protein content was estimated using the Western Blotting method.
Results. As a result of the study, it was noted that an increase in the VHL expression, together with a decrease in its protein level, was associated with an increase in tumor size. The prevalence of the disease was accompanied by an increase in both mRNA and VHL content in cancers. There was a negative correlation between the level of VHL expression, the content of the corresponding protein, and a positive association with the expression of NF-κB p65. VHL content in cancers was associated with decreased expression of NF-κB p50, NF-κB p65, and VEGF.
Discussion. An increase in VHL expression in tumor tissue promoted the growth of mRNA of transcription factors, in particular NF-κB, which is accompanied by tumor spread. An increase in the VHL protein content led to the suppression of the mRNA level of transcriptional and growth factors, which is probably associated with their inactivation, including through proteasome cleavage, and is an important stage in oncogenesis.
Conclusion. The relationship between the expression and content of the VHL protein is of decisive importance in the development of the disease, the formation of distant metastases.
References
Chung C. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer // Am J Health Syst Pharm. 2020;77(24):2064–2073. https://doi:10.1093/ajhp/zxaa308. PMID: 33016992
Kim BJ, Kim JH, Kim HS, Zang DY. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review // Oncotarget. 2017;8(8):13979–13985. https://doi:10.18632/oncotarget.14704
Lessi F, Mazzanti CM, Tomei S et al. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma // Med Oncol. 2014;31(3):840. https://doi:10.1007/s12032-014-0840-8 Epub 2014 Jan 21. PMID: 24446253.
Choueiri TK, Fay AP, Gagnon R et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma // Clin Cancer Res. 2013;19(18):5218–26. https://doi:10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23. PMID: 23881929; PMCID: PMC4522695.
Spirina LV, Usynin YA, Yurmazov ZA et al. Transcription factors NF-kB, HIF-1, HIF-2, growth factor VEGF, VEGFR2 and carboanhydrase IX mRNA and protein level in the development of kidney cancer metastasis // Mol Biol (Mosk). 2017;51(2):372–377. Russian. https://doi:10.7868/S0026898417020197. PMID: 28537244.
Spirina LV, Usynin EA, Yurmazov ZA et al. Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma // Asian Pac J Cancer Prev. 2017;18(11):2977–2983. https://doi:10.22034/APJCP.2017.18.11.2977. PMID: 29172268; PMCID: PMC5773780
Alves MR, Carneiro FC, Lavorato-Rocha AM et al. Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma // Virchows Arch. 2014;465(3):321–30. https://doi:10.1007/s00428-014-1629-z. Epub 2014 Jul 16. PMID: 25027579.
Ferchichi I, Kourda N, Sassi S et al. Aurora A overexpression and pVHL reduced expression are correlated with a bad kidney cancer prognosis // Dis Markers. 2012;33(6):333–40. https://doi:10.3233/DMA-2012-00942. PMID: 23151618; PMCID: PMC3810770.
Xiao-Fen W, Ting C, Jie L et al. Correlation analysis of VHL and Jade-1 gene expression in human renal cell carcinoma // Open Med (Wars). 2016;11(1):226–230. https://doi:10.1515/med-2016-0043
Spirina LV, Kondakova IV, Yurmazov ZA et al. VHL Expression in Kidney Cancer: Relation to Metastasis Development, Transcription and Growth Factors and Component of Akt/m-TOR Signaling Pathway // Bull Exp Biol Med. 2019;167(5):671–675. https://doi:10.1007/s10517-019-04596-9. Epub 2019 Oct 17. PMID: 31625068.
Kim DS, Choi YB, Han BG et al. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking // Oncogene. 2011;30(48):4780–90. https://doi:10.1038/onc.2011.183. Epub 2011 May 30. PMID: 21625219.
Yang H, Minamishima YA, Yan Q, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2 // Mol Cell. 2007;28(1):15–27. https://doi:10.1016/j.molcel.2007.09.010. PMID: 17936701; PMCID: PMC2128776.
Wang J, Ma Y, Jiang H et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice // J Hepatol. 2011;55(2):359–68. https://doi:10.1016/j.jhep.2010.10.043. Epub 2010 Dec 17. PMID: 21168458.
Walmsley SR, McGovern NN, Whyte MK, Chilvers ER. The HIF/VHL pathway: from oxygen sensing to innate immunity // Am J Respir Cell Mol Biol. 2008;38(3):251–5. https://doi:10.1165/rcmb.2007-0331TR. Epub 2007 Oct 11. PMID: 17932373.
Evans AJ, Russell RC, Roche O et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail // Mol Cell Biol. 2007;27(1):157–69. https://doi:10.1128/MCB.00892-06. Epub 2006 Oct 23. PMID: 17060462; PMCID: PMC1800649.
Arias-González L, Moreno-Gimeno I, del Campo AR et al. ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma // Neoplasia. 2013;15(6):649–59. https://doi:10.1593/neo.121896. PMID: 23730213; PMCID: PMC3664997.
Mikhaylova O, Stratton Y, Hall D et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma // Cancer Cell. 2012;21(4):532–46. https://doi:10.1016/j.ccr.2012.02.019. PMID: 22516261; PMCID: PMC3331999.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021